Stock Traders Buy High Volume of Call Options on OraSure Technologies (OSUR)

OraSure Technologies, Inc. (NASDAQ:OSUR) saw unusually large options trading on Thursday. Stock investors purchased 1,682 call options on the company. This represents an increase of 686% compared to the average volume of 214 call options.

A number of large investors have recently modified their holdings of OSUR. Ameriprise Financial Inc. lifted its stake in OraSure Technologies by 13.9% during the 2nd quarter. Ameriprise Financial Inc. now owns 637,522 shares of the medical instruments supplier’s stock valued at $11,004,000 after acquiring an additional 77,796 shares in the last quarter. Profund Advisors LLC lifted its stake in OraSure Technologies by 2.8% during the 2nd quarter. Profund Advisors LLC now owns 10,903 shares of the medical instruments supplier’s stock valued at $188,000 after acquiring an additional 293 shares in the last quarter. New York State Common Retirement Fund lifted its stake in OraSure Technologies by 20.2% during the 2nd quarter. New York State Common Retirement Fund now owns 61,800 shares of the medical instruments supplier’s stock valued at $1,067,000 after acquiring an additional 10,399 shares in the last quarter. Northern Trust Corp lifted its stake in OraSure Technologies by 6.0% during the 2nd quarter. Northern Trust Corp now owns 761,667 shares of the medical instruments supplier’s stock valued at $13,146,000 after acquiring an additional 43,407 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of OraSure Technologies by 19.8% during the 2nd quarter. Vanguard Group Inc. now owns 5,352,832 shares of the medical instruments supplier’s stock worth $92,390,000 after purchasing an additional 886,333 shares during the period. Institutional investors and hedge funds own 92.29% of the company’s stock.

A number of brokerages recently issued reports on OSUR. Zacks Investment Research upgraded OraSure Technologies from a “hold” rating to a “buy” rating and set a $23.00 target price on the stock in a report on Friday. Canaccord Genuity reiterated a “buy” rating and issued a $24.00 target price on shares of OraSure Technologies in a report on Friday, February 2nd. BidaskClub upgraded OraSure Technologies from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 20th. ValuEngine cut OraSure Technologies from a “buy” rating to a “hold” rating in a report on Thursday, November 2nd. Finally, Jefferies Group cut OraSure Technologies from a “buy” rating to a “hold” rating in a report on Thursday, November 2nd. Two research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $22.25.

OraSure Technologies (NASDAQ:OSUR) opened at $18.00 on Friday. OraSure Technologies has a 52 week low of $9.92 and a 52 week high of $23.01. The firm has a market capitalization of $1,066.20, a price-to-earnings ratio of 35.29, a price-to-earnings-growth ratio of 3.91 and a beta of 1.43.

OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings data on Wednesday, February 7th. The medical instruments supplier reported $0.12 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.01. OraSure Technologies had a return on equity of 13.09% and a net margin of 18.52%. The business had revenue of $52.00 million for the quarter, compared to analysts’ expectations of $50.20 million. During the same period last year, the business earned $0.13 EPS. The business’s revenue was up 46.5% on a year-over-year basis. equities analysts forecast that OraSure Technologies will post 0.36 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Stock Traders Buy High Volume of Call Options on OraSure Technologies (OSUR)” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/11/stock-traders-buy-high-volume-of-call-options-on-orasure-technologies-osur.html.

About OraSure Technologies

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply